REARRANGE trial shows benefits of flexible dosing pattern to treat refractory metastatic colorectal cancer

Written by Jenny Straiton, Future Science Group

In a recent international trial a team of researchers, led by the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), have demonstrated the usefulness of utilizing a more flexible dosing pattern to treat refractory-metastatic colorectal cancer.  Use of the drug Stivarga® (regorafenib) is often limited in clinical practice due to its potential for adverse effects. However, the results of the REARRANGE trial, recently presented at the ESMO World Congress on Gastrointestinal Cancer 2019 (Barcelona, Spain, 3–6 July), showed that altering the dosing regime can improve patients’ quality of life without having an effect on the efficacy of the...

To view this content, please register now for access

It's completely free